Pending further publication of clinical reports on the development of disease manifestations in patients with MEN4, it appears prudent to initiate screening of calcium and PTH levels in patients with MEN4 from the age of 15 years. The gene discussed is PTH; the disease is multiple endocrine neoplasia type 4.